TLX
Trans-Lux Corp.
NASDAQ · Healthcare · Biotechnology · AU
$12.59
+0.68%Next report
Analyst consensus
- Next report date
- Feb 19, 2027
- EPS estimate
- -$0.02
- Revenue estimate
- $494.6M
Latest reported
- Last report date
- Aug 19, 2026
- EPS actual
- $0.11
- EPS estimate
- $0.04
- Revenue actual
- $477.0M
- Revenue estimate
- $479.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +33.2%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $21
- PT range
- $20 – $22
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 19, 2026 | $0.04 | $0.11 | Beat 140.27% | $477.0M |
| Feb 19, 2026 | $0.04 | -$0.01 | Miss -135.72% | $414.0M |
| Aug 20, 2025 | -$0.14 | -$0.01 | Beat 95.13% | $388.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 19, 2027